OncoMatch/Clinical Trials/NCT05709249
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Is NCT05709249 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies XLJDOD compound granule for colon cancer.
Treatment: XLJDOD compound granule — This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IIIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: surgical resection
Completion of surgical resection of tumors with negative margins (R0 resection)
Must have received: adjuvant chemotherapy (5-fluorouracil, capecitabine, oxaliplatin, leucovorin) — adjuvant
at least 3 months of adjuvant chemotherapy based on 5-fluorouracil (5-FU). 4 cycles of CAPOX (capecitabine and oxaliplatin), 6 cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) or 4 cycles of single agent-5-FU, etc.
Cannot have received: adjuvant radiotherapy
other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer
Cannot have received: adjuvant targeted therapy
other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer
Cannot have received: adjuvant immunotherapy
other adjuvant therapy such as radiotherapy, targeted therapy and immunotherapy has been used to treat colon cancer
Cannot have received: antitumor Chinese patent medicine and decoction
Antitumor Chinese patent medicine and decoction have been used for more than 3 months after surgery or within 1 month before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05709249 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adjuvant radiotherapy, adjuvant targeted therapy, adjuvant immunotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIIB or IIIC is required.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 20 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages